The group will use IsoPlexis' single-cell proteomics platform to analyze immune cells from patients who have been diagnosed or recovered from COVID-19.
Researchers found that small-molecule inhibitors targeting oncogenic signal transduction or epigenetic regulation can alter specific 3D interactions in leukemia.
The team has begun analyzing additional analytes in HER2-positive breast cancer patients and will present preliminary results at AACR's annual meeting in May.
